Genetic modifiers of ambulation in the cooperative international Neuromuscular research group Duchenne natural history study

Annals of Neurology

Volumn 77, Issue 4, 2015, Pages 684-696

  Bello, Luca ^a,b   Kesari, Akanchha ^a   Gordish Dressman, Heather ^a   Cnaan, Avital ^a,c   Morgenroth, Lauren P ^a   Punetha, Jaya ^a,c   Duong, Tina ^a   Henricson, Erik K ^d   Pegoraro, Elena ^b   McDonald, Craig M ^d   Hoffman, Eric P ^a,c  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF PADOVA   (Italy)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; GLUCOCORTICOID; LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN; LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN 4; OSTEOPONTIN; UNCLASSIFIED DRUG; LTBP4 PROTEIN, HUMAN; SPP1 PROTEIN, HUMAN;

ADOLESCENT; ADULT; AFRICAN AMERICAN; ARTICLE; ASIAN; CAUCASIAN; CHILD; CORTICOSTEROID THERAPY; DISABILITY; DUCHENNE MUSCULAR DYSTROPHY; ETHNICITY; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HETEROZYGOTE; HISPANIC; HOMOZYGOTE; HUMAN; LOSS OF AMBULATION; MAJOR CLINICAL STUDY; ONSET AGE; PRESCHOOL CHILD; PRIORITY JOURNAL; RACE DIFFERENCE; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; SOUTH ASIAN; YOUNG ADULT; COHORT ANALYSIS; ETHNIC GROUP; ETHNOLOGY; GENETICS; INTERNATIONAL COOPERATION; MALE; MUSCULAR DYSTROPHY, DUCHENNE; WALKING; WALKING DIFFICULTY;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; ETHNIC GROUPS; HUMANS; INTERNATIONAL COOPERATION; LATENT TGF-BETA BINDING PROTEINS; MALE; MOBILITY LIMITATION; MUSCULAR DYSTROPHY, DUCHENNE; OSTEOPONTIN; WALKING; YOUNG ADULT;

EID: 84925643643     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24370     Document Type: Article

References (33)

1. Hoffman EP, Brown RH Jr, Kunkel LM,. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987; 51: 919-928.
2. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010; 9: 77-93.
3. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 2010; 9: 177-189.
4. Pegoraro E, Hoffman EP, Piva L, et al. SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy. Neurology 2011; 76: 219-226.
5. Ceco E, McNally EM,. Modifying muscular dystrophy through transforming growth factor-beta. FEBS J 2013; 280: 4198-4209.
6. Giacopelli F, Marciano R, Pistorio A, et al. Polymorphisms in the osteopontin promoter affect its transcriptional activity. Physiol Genomics 2004; 20: 87-96.
7. Barfield WL, Uaesoontrachoon K, Wu CS, et al. Eccentric muscle challenge shows osteopontin polymorphism modulation of muscle damage. Hum Mol Genet 2014; 23: 4043-4050.
8. Heydemann A, Ceco E, Lim JE, et al. Latent TGF-beta-binding protein 4 modifies muscular dystrophy in mice. J Clin Invest 2009; 119: 3703-3712.
9. Flanigan KM, Ceco E, Lamar KM, et al. LTBP4 genotype predicts age of ambulatory loss in Duchenne muscular dystrophy. Ann Neurol 2013; 73: 481-488.
10. Nelson SF, Griggs RC,. Predicting the severity of Duchenne muscular dystrophy: implications for treatment. Neurology 2011; 76: 208-209.
11. Enoch MA, Shen PH, Xu K, et al. Using ancestry-informative markers to define populations and detect population stratification. J Psychopharmacol 2006; 20 (4 suppl): 19-26.
12. Tian C, Gregersen PK, Seldin MF,. Accounting for ancestry: population substructure and genome-wide association studies. Hum Mol Genet 2008; 17: R143-R150.
13. Genin E, Feingold J, Clerget-Darpoux F,. Identifying modifier genes of monogenic disease: strategies and difficulties. Hum Genet 2008; 124: 357-368.
14. Holtzer C, Meaney FJ, Andrews J, et al. Disparities in the diagnostic process of Duchenne and Becker muscular dystrophy. Genet Med 2011; 13: 942-947.
15. Fox DJ, Kumar A, West NA, et al. Trends with corticosteroid use in males with Duchenne muscular dystrophy born 1982-2001. J Child Neurol 2015; 30: 21-26.
16. Bortolini ER, Zatz M,. Duchenne muscular dystrophy: comparison among different racial groups. Am J Med Genet 1987; 28: 925-929.
17. Kenneson A, Kolor K, Yang Q, et al. Trends and racial disparities in muscular dystrophy deaths in the United States, 1983-1998: an analysis of multiple cause mortality data. Am J Med Genet A 2006; 140: 2289-2297.
18. McDonald CM, Henricson EK, Abresch RT, et al. The Cooperative International Neuromuscular Research Group Duchenne Natural History Study-a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used. Muscle Nerve 2013; 48: 32-54.
19. Henricson EK, Abresch RT, Cnaan A, et al. The Cooperative International Neuromuscular Research Group Duchenne Natural History Study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures. Muscle Nerve 2013; 48: 55-67.
20. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575.
21. Neale BM, Purcell S,. The positives, protocols, and perils of genome-wide association. Am J Med Genet B 2008; 147B: 1288-1294.
22. DeSilva S, Drachman DB, Mellits D, Kuncl RW,. Prednisone treatment in Duchenne muscular dystrophy. Long-term benefit. Arch Neurol 1987; 44: 818-822.
23. Angelini C, Pegoraro E, Turella E, et al. Deflazacort in Duchenne dystrophy: study of long-term effect. Muscle Nerve 1994; 17: 386-391.
24. McAdam LC, Mayo AL, Alman BA, Biggar WD,. The Canadian experience with long-term deflazacort treatment in Duchenne muscular dystrophy. Acta Myol 2012; 31: 16-20.
25. Ricotti V, Ridout DA, Scott E, et al. Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. J Neurol Neurosurg Psychiatry 2013; 84: 698-705.
26. Bello L, Piva L, Barp A, et al. Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy. Neurology 2012; 79: 159-162.
27. Piva L, Gavassini BF, Bello L, et al. TGFBR2 but not SPP1 genotype modulates osteopontin expression in Duchenne muscular dystrophy muscle. J Pathol 2012; 228: 251-259.
28. Hoffman EP, Gordish-Dressman H, McLane VD, et al. Alterations in osteopontin modify muscle size in females in both humans and mice. Med Sci Sports Exerc 2013; 45: 1060-1068.
29. Rhen T, Cidlowski JA,. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N Engl J Med 2005; 353: 1711-1723.
30. Fisher I, Abraham D, Bouri K, et al. Prednisolone-induced changes in dystrophic skeletal muscle. FASEB J 2005; 19: 834-836.
31. Heier CR, Damsker JM, Yu Q, et al. VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects. EMBO Mol Med 2013; 5: 1569-1585.
32. van den Bergen JC, Hiller M, Bohringer S, et al. Validation of genetic modifiers for Duchenne muscular dystrophy: a multicentre study assessing SPP1 and LTBP4 variants. J Neurol Neurosurg Psychiatry 2014;DOI: 10.1136/jnnp-2014-308409. [Epub ahead of print]
33. Zatz M, Pavanello RC, Lazar M, et al. Milder course in Duchenne patients with nonsense mutations and no muscle dystrophin. Neuromuscul Disord 2014; 24: 986-989.